Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CGT6297 in Advanced Solid Tumors With PIK3CA Mutations
NCT07383506Phase 1Recruiting
- Sponsor
- Cogent Biosciences
- Start
- Jul 2026
- Primary completion
- Jul 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of CGT6297 in solid tumor, endometrial cancer (EC), breast cancer and 2 more (2 arms), sponsored by Cogent Biosciences. Primary endpoints: Incidence and grade of Adverse Events and Serious Adverse Events at 12 months and Overall Response Rate at 8 months. Started Jul 2026; status: recruiting.
02
Drugs
CGT6297
03
Conditions
solid tumorendometrial cancer (EC)breast cancerhead and neck cancer (HNC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07383506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07383506.